Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Patent disputes haven't materialized in the RNAi field yet, but once products near the market, it might be a different story. Charlie Schmidt investigates.
Designing clinical trials that adapt midstream is billed as a cure for drug development blues, one that can save time, money and improve patients' lives. Are these new designs safe and effective or an expensive gimmick?
What academic disciplines play a major role in the education, training and development of young scientists who are integrating nanotechnology with biomedical research?
